Do analysts rate LIAN or SHPH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Shuttle Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, LIAN or SHPH?

LianBio is trading at a lower price-to-earnings ratio than Shuttle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LianBio N/A N/A -$110.29M -$0.81 N/A Shuttle Pharmaceuticals N/A N/A -$11.72M -$4.77 N/A

Is LIAN or SHPH more profitable?

LianBio's return on equity of -33.17% beat Shuttle Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets LianBio N/A -33.17% -30.19% Shuttle Pharmaceuticals N/A -408.34% -138.15%

Do analysts rate SHPH or KPRX?

Kiora Pharmaceuticals has a consensus price target of $10.00, suggesting a potential upside of 300.00%. Given Kiora Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Kiora Pharmaceuticals is more favorable than Shuttle Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Shuttle Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Kiora Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is SHPH or KPRX more profitable?

Kiora Pharmaceuticals' return on equity of -59.30% beat Shuttle Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Shuttle Pharmaceuticals N/A -408.34% -138.15% Kiora Pharmaceuticals N/A -59.30% -41.23%

Do analysts rate FNCH or SHPH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Shuttle Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, FNCH or SHPH?

Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Shuttle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Finch Therapeutics Group N/A N/A -$74.75M -$8.82 N/A Shuttle Pharmaceuticals N/A N/A -$11.72M -$4.77 N/A

Is FNCH or SHPH more profitable?

Finch Therapeutics Group's return on equity of -69.14% beat Shuttle Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Finch Therapeutics Group N/A -69.14% -26.92% Shuttle Pharmaceuticals N/A -408.34% -138.15%

Do analysts prefer NXTC or SHPH?

NextCure currently has a consensus price target of $23.00, suggesting a potential upside of 679.66%. Given NextCure's stronger consensus rating and higher probable upside, equities analysts clearly believe NextCure is more favorable than Shuttle Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NextCure 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20 Shuttle Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, NXTC or SHPH?

NextCure is trading at a lower price-to-earnings ratio than Shuttle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NextCure N/A N/A -$55.84M -$17.19 N/A Shuttle Pharmaceuticals N/A N/A -$11.72M -$4.77 N/A

Is NXTC or SHPH more profitable?

NextCure's return on equity of -186.96% beat Shuttle Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets NextCure N/A -186.96% -124.62% Shuttle Pharmaceuticals N/A -408.34% -138.15%

Do analysts prefer HCWB or SHPH?

HCW Biologics currently has a consensus price target of $5.00, suggesting a potential upside of 206.75%. Given HCW Biologics' stronger consensus rating and higher probable upside, equities analysts plainly believe HCW Biologics is more favorable than Shuttle Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HCW Biologics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Shuttle Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Shuttle Pharmaceuticals (SHPH) Competitors

$0.45 -0.04 (-7.82%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$0.43 -0.03 (-5.95%)

As of 06/5/2026 07:59 PM Eastern

Compare

SHPH vs. LIAN, KPRX, FNCH, NXTC, and HCWB

Should you buy Shuttle Pharmaceuticals stock or one of its competitors? MarketBeat compares Shuttle Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Shuttle Pharmaceuticals include LianBio (LIAN), Kiora Pharmaceuticals (KPRX), Finch Therapeutics Group (FNCH), NextCure (NXTC), and HCW Biologics (HCWB). These companies are all part of the "pharmaceutical products" industry.

How does Shuttle Pharmaceuticals compare to LianBio?

LianBio (NASDAQ:LIAN) and Shuttle Pharmaceuticals (NASDAQ:SHPH) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

74.8% of LianBio shares are held by institutional investors. Comparatively, 4.6% of Shuttle Pharmaceuticals shares are held by institutional investors. 7.6% of LianBio shares are held by insiders. Comparatively, 12.6% of Shuttle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

LianBio's return on equity of -33.17% beat Shuttle Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LianBio	N/A	-33.17%	-30.19%
Shuttle Pharmaceuticals	N/A	-408.34%	-138.15%

LianBio is trading at a lower price-to-earnings ratio than Shuttle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A
Shuttle Pharmaceuticals	N/A	N/A	-$11.72M	-$4.77	N/A

In the previous week, LianBio's average media sentiment score of 0.00 equaled Shuttle Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
LianBio	Neutral
Shuttle Pharmaceuticals	Neutral

LianBio has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, Shuttle Pharmaceuticals has a beta of 0.18, suggesting that its stock price is 82% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Shuttle Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

LianBio beats Shuttle Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

How does Shuttle Pharmaceuticals compare to Kiora Pharmaceuticals?

Shuttle Pharmaceuticals (NASDAQ:SHPH) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

Kiora Pharmaceuticals has a consensus price target of $10.00, suggesting a potential upside of 300.00%. Given Kiora Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Kiora Pharmaceuticals is more favorable than Shuttle Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shuttle Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Kiora Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Shuttle Pharmaceuticals' average media sentiment score of 0.00 equaled Kiora Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Shuttle Pharmaceuticals	Neutral
Kiora Pharmaceuticals	Neutral

4.6% of Shuttle Pharmaceuticals shares are held by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 12.6% of Shuttle Pharmaceuticals shares are held by insiders. Comparatively, 0.1% of Kiora Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Kiora Pharmaceuticals has higher revenue and earnings than Shuttle Pharmaceuticals. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Shuttle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shuttle Pharmaceuticals	N/A	N/A	-$11.72M	-$4.77	N/A
Kiora Pharmaceuticals	$16.02M	0.69	-$10.84M	-$2.71	N/A

Shuttle Pharmaceuticals has a beta of 0.18, indicating that its share price is 82% less volatile than the broader market. Comparatively, Kiora Pharmaceuticals has a beta of -0.4, indicating that its share price is 140% less volatile than the broader market.

Kiora Pharmaceuticals' return on equity of -59.30% beat Shuttle Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shuttle Pharmaceuticals	N/A	-408.34%	-138.15%
Kiora Pharmaceuticals	N/A	-59.30%	-41.23%

Summary

Kiora Pharmaceuticals beats Shuttle Pharmaceuticals on 9 of the 11 factors compared between the two stocks.

How does Shuttle Pharmaceuticals compare to Finch Therapeutics Group?

Finch Therapeutics Group (NASDAQ:FNCH) and Shuttle Pharmaceuticals (NASDAQ:SHPH) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Shuttle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A
Shuttle Pharmaceuticals	N/A	N/A	-$11.72M	-$4.77	N/A

In the previous week, Finch Therapeutics Group's average media sentiment score of 0.00 equaled Shuttle Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Finch Therapeutics Group	Neutral
Shuttle Pharmaceuticals	Neutral

Finch Therapeutics Group has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market. Comparatively, Shuttle Pharmaceuticals has a beta of 0.18, indicating that its stock price is 82% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Finch Therapeutics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Shuttle Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

21.8% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 4.6% of Shuttle Pharmaceuticals shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by company insiders. Comparatively, 12.6% of Shuttle Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Finch Therapeutics Group's return on equity of -69.14% beat Shuttle Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Finch Therapeutics Group	N/A	-69.14%	-26.92%
Shuttle Pharmaceuticals	N/A	-408.34%	-138.15%

Summary

Finch Therapeutics Group beats Shuttle Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

How does Shuttle Pharmaceuticals compare to NextCure?

NextCure (NASDAQ:NXTC) and Shuttle Pharmaceuticals (NASDAQ:SHPH) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.

In the previous week, NextCure had 4 more articles in the media than Shuttle Pharmaceuticals. MarketBeat recorded 4 mentions for NextCure and 0 mentions for Shuttle Pharmaceuticals. Shuttle Pharmaceuticals' average media sentiment score of 0.00 beat NextCure's score of -0.43 indicating that Shuttle Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
NextCure	Neutral
Shuttle Pharmaceuticals	Neutral

NextCure currently has a consensus price target of $23.00, suggesting a potential upside of 679.66%. Given NextCure's stronger consensus rating and higher probable upside, equities analysts clearly believe NextCure is more favorable than Shuttle Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NextCure	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Shuttle Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NextCure's return on equity of -186.96% beat Shuttle Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NextCure	N/A	-186.96%	-124.62%
Shuttle Pharmaceuticals	N/A	-408.34%	-138.15%

NextCure has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market. Comparatively, Shuttle Pharmaceuticals has a beta of 0.18, meaning that its stock price is 82% less volatile than the broader market.

NextCure is trading at a lower price-to-earnings ratio than Shuttle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NextCure	N/A	N/A	-$55.84M	-$17.19	N/A
Shuttle Pharmaceuticals	N/A	N/A	-$11.72M	-$4.77	N/A

42.7% of NextCure shares are owned by institutional investors. Comparatively, 4.6% of Shuttle Pharmaceuticals shares are owned by institutional investors. 11.9% of NextCure shares are owned by company insiders. Comparatively, 12.6% of Shuttle Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

NextCure beats Shuttle Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Shuttle Pharmaceuticals compare to HCW Biologics?

HCW Biologics (NASDAQ:HCWB) and Shuttle Pharmaceuticals (NASDAQ:SHPH) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

HCW Biologics has higher revenue and earnings than Shuttle Pharmaceuticals. HCW Biologics is trading at a lower price-to-earnings ratio than Shuttle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HCW Biologics	$50K	219.40	-$7.96M	-$9.46	N/A
Shuttle Pharmaceuticals	N/A	N/A	-$11.72M	-$4.77	N/A

Shuttle Pharmaceuticals has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. Shuttle Pharmaceuticals' return on equity of -408.34% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HCW Biologics	-34.73%	-486.87%	-29.19%
Shuttle Pharmaceuticals	N/A	-408.34%	-138.15%

HCW Biologics has a beta of 2.21, suggesting that its share price is 121% more volatile than the broader market. Comparatively, Shuttle Pharmaceuticals has a beta of 0.18, suggesting that its share price is 82% less volatile than the broader market.

HCW Biologics currently has a consensus price target of $5.00, suggesting a potential upside of 206.75%. Given HCW Biologics' stronger consensus rating and higher probable upside, equities analysts plainly believe HCW Biologics is more favorable than Shuttle Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Shuttle Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, HCW Biologics had 1 more articles in the media than Shuttle Pharmaceuticals. MarketBeat recorded 1 mentions for HCW Biologics and 0 mentions for Shuttle Pharmaceuticals. HCW Biologics' average media sentiment score of 0.80 beat Shuttle Pharmaceuticals' score of 0.00 indicating that HCW Biologics is being referred to more favorably in the media.

Company	Overall Sentiment
HCW Biologics	Positive
Shuttle Pharmaceuticals	Neutral

3.0% of HCW Biologics shares are held by institutional investors. Comparatively, 4.6% of Shuttle Pharmaceuticals shares are held by institutional investors. 9.1% of HCW Biologics shares are held by insiders. Comparatively, 12.6% of Shuttle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

HCW Biologics beats Shuttle Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Get Shuttle Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SHPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SHPH vs. The Competition

Export

Metric	Shuttle Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.66M	$2.96B	$6.64B	$12.42B
Dividend Yield	N/A	1.70%	2.68%	5.34%
P/E Ratio	-0.10	18.12	23.84	23.63
Price / Sales	N/A	706.49	577.54	137.68
Price / Cash	N/A	56.21	42.42	57.17
Price / Book	0.41	3.83	9.73	6.35
Net Income	-$11.72M	$75.85M	$3.57B	$337.59M
7 Day Performance	-13.52%	-1.85%	-1.26%	-2.51%
1 Month Performance	-41.79%	-7.67%	0.82%	-0.69%
1 Year Performance	-90.10%	14.97%	24.09%	25.37%

Shuttle Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SHPH Shuttle Pharmaceuticals	0.2106 of 5 stars	$0.45 -7.8%	N/A	-89.6%	$2.66M	N/A	N/A	5	Gap Down
LIAN LianBio	N/A	$0.11 flat	N/A	-63.3%	$11.91M	N/A	N/A	110	Gap Down
KPRX Kiora Pharmaceuticals	2.6043 of 5 stars	$2.66 -2.2%	$10.00 +275.9%	-19.1%	$11.79M	N/A	N/A	10	Positive News
FNCH Finch Therapeutics Group	N/A	$7.30 flat	N/A	N/A	$11.72M	N/A	N/A	190
NXTC NextCure	3.2319 of 5 stars	$3.23 -5.1%	$23.00 +612.5%	-50.4%	$11.65M	N/A	N/A	90	News Coverage High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SHPH) was last updated on 6/6/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Shuttle Pharmaceuticals (SHPH) Competitors

SHPH vs. LIAN, KPRX, FNCH, NXTC, and HCWB

How does Shuttle Pharmaceuticals compare to LianBio?

Summary

How does Shuttle Pharmaceuticals compare to Kiora Pharmaceuticals?

Summary

How does Shuttle Pharmaceuticals compare to Finch Therapeutics Group?

Summary

How does Shuttle Pharmaceuticals compare to NextCure?

Summary

How does Shuttle Pharmaceuticals compare to HCW Biologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SHPH vs. The Competition

Shuttle Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Shuttle Pharmaceuticals (SHPH) Competitors

SHPH vs. LIAN, KPRX, FNCH, NXTC, and HCWB

How does Shuttle Pharmaceuticals compare to LianBio?

Do institutionals and insiders hold more shares of LIAN or SHPH?

Is LIAN or SHPH more profitable?

Which has preferable earnings & valuation, LIAN or SHPH?

Does the media favor LIAN or SHPH?

Which has more risk and volatility, LIAN or SHPH?

Do analysts rate LIAN or SHPH?

Summary

How does Shuttle Pharmaceuticals compare to Kiora Pharmaceuticals?

Do analysts rate SHPH or KPRX?

Does the media prefer SHPH or KPRX?

Do institutionals & insiders hold more shares of SHPH or KPRX?

Which has higher earnings & valuation, SHPH or KPRX?

Which has more risk & volatility, SHPH or KPRX?

Is SHPH or KPRX more profitable?

Summary

How does Shuttle Pharmaceuticals compare to Finch Therapeutics Group?

Which has stronger valuation & earnings, FNCH or SHPH?

Does the media prefer FNCH or SHPH?

Which has more volatility & risk, FNCH or SHPH?

Do analysts rate FNCH or SHPH?

Do insiders & institutionals hold more shares of FNCH or SHPH?

Is FNCH or SHPH more profitable?

Summary

How does Shuttle Pharmaceuticals compare to NextCure?

Does the media favor NXTC or SHPH?

Do analysts prefer NXTC or SHPH?

Is NXTC or SHPH more profitable?

Which has more volatility & risk, NXTC or SHPH?

Which has higher valuation & earnings, NXTC or SHPH?

Do insiders and institutionals hold more shares of NXTC or SHPH?

Summary

How does Shuttle Pharmaceuticals compare to HCW Biologics?

Which has preferable earnings & valuation, HCWB or SHPH?

Is HCWB or SHPH more profitable?

Which has more volatility & risk, HCWB or SHPH?

Do analysts prefer HCWB or SHPH?

Does the media favor HCWB or SHPH?

Do institutionals & insiders have more ownership in HCWB or SHPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SHPH vs. The Competition

Shuttle Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools